CAR-T Cell Therapy For Cancer: The Patient's In The Process

By Georgia Lewis

Autologous cell therapies require a fundamental shift in manufacturing philosophy. Unlike traditional pharmaceuticals produced in bulk, personalised treatments treat the patient's own cells as the starting material. Each batch represents a single patient's therapeutic opportunity, leaving zero room for product loss or contamination.

Maintaining live cell viability across every step is paramount. The cryovial filling stage presents a critical bottleneck: cryoprotectants protect cells during freezing but introduce toxicity during handling. Manual pipette operations risk variable fill volumes, prolonged ambient exposure, and contamination. Transitioning to automated filling standardizes processing times, enforces closed-system environmental control, and protects post-thaw cell health. Explore strategies for engineering repeatability into fragile cell therapy workflows.